Patient-driven drug pricing, the uncertain future of Switzerland’s tax regime, and new business models for life science innovators in a changing global market are just a few of the topics touched upon by KPMG Switzerland’s head of life sciences Martin Rohrbach.
On February 12th the Swiss people rejected the Tax III reform via referendum. What does this mean for the Swiss business community?
"I’m confident that Switzerland remains one of the most competitive and attractive business environments in the world, especially for life science companies."
